MEDI7219 is a bis-lipidated glucagon-like peptide-1 (GLP-1) analog providing enhanced circulation time by reversible binding to albumin. It was being developed as an oral formulation to improve glycemic control and body weight loss in patients with Type 2 diabetes . As most currently available GLP-1 receptor agonists are administered via subcutaneous (SC) injection, MEDI7219 may provide a better option for patients by increasing compliance and ease-of-use.